Presence of antiphospholipid antibodies in COVID-19: a case series study
| Autor: | Yaneli Juárez-Vicuña, Claudia Tavera-Alonso, Armando Vazquez-Rangel, Malinalli Brianza-Padilla, Luis M. Amezcua-Guerra, Marisol Hernández-Salas, Fausto Sánchez-Muñoz, Gustavo Rojas-Velasco, Ricardo Márquez-Velasco, Francisco M. Baranda-Tovar, Rashidi Springall, Héctor González-Pacheco |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Immunology General Biochemistry Genetics and Molecular Biology law.invention 03 medical and health sciences 0302 clinical medicine Rheumatology immune system diseases Antiphospholipid syndrome law Internal medicine medicine Coagulopathy Immunology and Allergy Humans skin and connective tissue diseases 030203 arthritis & rheumatology Lupus anticoagulant Hematology business.industry SARS-CoV-2 COVID-19 Hydroxychloroquine medicine.disease Thrombosis Intensive care unit 030104 developmental biology Antibodies Anticardiolipin Antibodies Antiphospholipid business medicine.drug Case series |
| Zdroj: | Annals of the Rheumatic Diseases |
| ISSN: | 1468-2060 |
| Popis: | The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and its associated coagulopathy are particularly worrisome in patients with systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS), as these diseases carry an increased risk of thrombotic complications. Mathian et al recently reported the clinical course of COVID-19 in a series of 17 patients with SLE under chronic hydroxychloroquine therapy.1 Of note, only one patient (6%) presented thrombosis despite the fact that four patients (24%) had a history of secondary APS, and five patients (29%) were receiving oral anticoagulants. Antiphospholipid (aPL) antibodies were not measured in these patients during active SARS-CoV-2 infection.1 The American Society of Hematology recently stated that ‘at the current time, there are only very limited data on aPL antibodies in COVID-19 and it is unclear if they represent an epiphenomenon or are actually involved in any haemostatic abnormalities seen in COVID-19 disease’.2 Furthermore, almost all the available information refers to the lupus anticoagulant, with frequencies ranging from 45% to 87%.3 4 This paucity of data led us to test a panel of aPL antibodies in blood specimens from 21 patients hospitalised in the intensive care unit between 12 and 19 … |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|